TRAW today
$0.28+$0.03 (+12.68%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minBearish
5 minStrong Bullish
Daily trend turns up above $0.31
Key levels
Resistance$0.36
Resistance$0.31
Support$0.22
Latest news & SEC filings
ProductTraws Pharma moves oral COVID-19 and monthly flu antiviral programs toward next milestones
ProductTraws Pharma releases last Phase 2a COVID-19 results, pushes influenza drug ahead
All TRAW news →About Traws Pharma
Traws Pharma develops experimental medicines aimed at serious respiratory viral infections. Its pipeline features tivoxavir marboxil for influenza and bird flu, ratutrelvir for COVID-19, plus the oncology candidates narazaciclib and rigosertib. The firm targets patients battling these viral illnesses and cancers, runs studies in the United States and Australia, and has a partner handling narazaciclib in China.
Based on the company's 10-K filed Apr 15, 2026.
Nasdaq · Healthcare
Traws Pharma, Inc. (TRAW)
What Is the Price Target for TRAW?
SEPT Low Target
$1.00
SEPT Mid Target
$1.00
SEPT High Target
$1.00
Analyst Consensus
$1.00
Is TRAW a Buy or Sell Right Now?
Thesis
- •Revenue growing 1134.5% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TRAW.
Start Free Trial →Is TRAW Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.21
18
Moat Score
NONE
4/9
Piotroski Score
-89.9
Altman Z-Score
What Is Smart Money Doing with TRAW?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TRAW Growth Story
Revenue YoY
1134.5%
3yr Revenue CAGR
131.1%
EPS Growth YoY
102.33%
FCF Growth YoY
37.9%
Revenue Trend
ACCELERATING
Dark Pool Trades for TRAW
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TRAW, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:50:36 | $0.28 | 1,000 | $$275 | SELL |
| 24:50:18 | $0.28 | 1,000 | $$275 | SELL |
| 24:48:50 | $0.28 | 1,000 | $$275 | SELL |
| 21:23:52 | $0.28 | 3,471 | $$981 | BUY |
| 20:56:55 | $0.28 | 5,500 | $$2K | SELL |
5 dark pool trades shown · $$3K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Traws Pharma, Inc. (TRAW) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TRAW — frequently asked questions
What is TRAW stock price today?
Traws Pharma, Inc. (TRAW) is at $0.28, up 12.68% (+$0.03) at the Nov 12, 2026 close.
Why is TRAW stock moving today?
Latest TRAW news — Nov 12, 2026: Traws Pharma moves oral COVID-19 and monthly flu antiviral programs toward next milestones · Nov 12, 2026: Traws Pharma releases last Phase 2a COVID-19 results, pushes influenza drug ahead
What is the TRAW price target?
The average analyst price target for TRAW is $1.00, ranging from $1 to $1, based on 1 analysts. Latest: HC Wainwright & Co. downgrade on Jun 18, 2026.
What do analysts rate TRAW?
Analyst ratings for TRAW: 0 Buy, 2 Hold, 2 Sell — consensus Hold.
Did TRAW beat earnings?
TRAW last reported on Aug 14, 2026: EPS -$0.16 vs -$0.34 expected — a beat of 52.2%.
Does TRAW pay a dividend?
TRAW does not currently pay a dividend.
What are TRAW support and resistance levels?
Support: $0.22. Resistance: $0.31, $0.36, $0.43.
What are insiders doing with TRAW?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on TRAW?
Nov 12, 2026: Traws Pharma moves oral COVID-19 and monthly flu antiviral programs toward next milestones · Nov 12, 2026: Traws Pharma releases last Phase 2a COVID-19 results, pushes influenza drug ahead